GlassScriptPhysician profile
Carlos R Ramirez-Ramirez
NPI 1194793166
$1,241.36
in general payments reported to CMS, 2019-2025
18 companies · $238 in 2025
The $238 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $92.99 · 2020: $78.44 · 2021: $68.75 · 2022: $230 · 2023: $306 · 2024: $227 · 2025: $238.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $771.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $771.07 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $212.07 | 2020-2023 | Arexvy, Trelegy Ellipta |
| Amgen INC. | $205.06 | 2020-2024 | Repatha, Otezla |
| Pfizer INC. | $148.86 | 2019-2024 | |
| Emd Serono, INC. | $136.06 | 2025 | |
| Novartis Pharmaceuticals Corporation | $99.42 | 2020-2023 | |
| Lilly USA, LLC | $76.74 | 2021-2025 | Mounjaro, Emgality, Jardiance |
| Abbvie INC. | $67.43 | 2023-2024 | |
| Kls-Martin L.P. | $65.66 | 2025 | |
| Exact Sciences Corporation | $59.60 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Paratek Pharmaceuticals, INC. | $32.72 | 2022-2024 | Nuzyra |
| Abbott Laboratories | $22.23 | 2024 | Freestyle Libre 3 |
| Novo Nordisk INC | $22.07 | 2022 | |
| Janssen Pharmaceuticals, INC | $20.90 | 2019 | |
| Astellas Pharma US INC | $17.08 | 2021 | |
| Shield Therapeutics INC | $15.72 | 2024 |
Show all 18 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $13.91 | 2023 | Quviviq |
| Boehringer Ingelheim Pharmaceuticals, INC. | $13.58 | 2024 | Jardiance |
| Viiv Healthcare Company | $12.25 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Ramirez-Ramirez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.